Figure 7

Effects of gene transfer of constitutively active ERK, AKT or GFP phosphorylation (A-D) Western Blot of HUVEC after treatment with FGF2, infected with the GFP, ca ERK or ca AKT adenoviral constructs, or treated with FGF2 and infected with adenoviral constructs. The same Western blot was used for all antibodies after stripping and rehybridizing. A) Reacted with anti-phospho ERK antibody (B) reacted with anti-total ERK antibody. (C) Reacted with anti-phospho AKT antibody. (D) Reacted with anti-total AKT antibody. (E) Immuno-complex assay showing changes in ERK activity with or without FGF2 treatment in HUVEC with caERK, caAKT or GFP. (F) Quantification of ERK activity levels in HUVEC +/- FGF2 treatment with caERK, caAKT or GFP with the PhosphorImager as described in the Materials and Methods. * indicates a significant difference from control. * = P < 0.05 by One-Way ANOVA with post-hoc Dunnett's when compared to control.